Breast Cancer
Conditions
Interventions
Group A: Anti-tumor treatment + Proteinuria treatment + Huaier Granules treatment
:Combination of Huaier Granules on the basis of conventional anti-tumor treatment and proteinuria treatment
Group B: Anti-tumor treatment + Proteinuria treatment:Conventional anti-tumor treatment and proteinuria treatment
Sponsors
Fudan University Shanghai Cancer Center
Eligibility
Sex/Gender
Female
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Women aged 18-75 years; 2. Clinically diagnosed with breast cancer as judged by the investigator; 3. Current or previous immunotherapy, or anti-vascular therapy; 4. Proteinuria in routine urine examination is +/++/+++ for the first time; 5.0.15g<24h urine protein quantification<3.5g; 6. ECOG score: 0~1 points; 7. KPS score =70; 8. No treatment with locust ear granules within 1 month before enrollment; 9. Expected survival time not less than 6 months; 10. Volunteer to join this study and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Known history of chronic kidney disease (eGFR<60 ml/min/1.73m²) or diabetic nephropathy; 2. Proteinuria caused by diseases, including but not limited to kidney disease, hypertension, urinary system infection, systemic lupus erythematosus, multiple myeloma, etc.; 3. Current use of ACEI/ARB drugs (stable dose = 4 weeks before enrollment is allowed); 4. Known allergy to the components of locust ear granules or avoid using and use locust ear granules with caution; 5. Pregnant or lactating women or planning to become pregnant; 6. Participating in other clinical trials of proteinuria drugs; 7. Other reasons that make the investigator unsuitable for participating in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Effective rate of proteinuria treatment after 8 weeks of Huaier Granules therapy;; | — |
Countries
China
Contacts
Public ContactZhi-Ming Shao
Fudan University Shanghai Cancer Center
Outcome results
None listed